Physician profile
Robert Elton Tonsing
NPI 1770528630
$3,011.62
in general payments reported to CMS, 2019-2025
23 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $397 · 2021: $473 · 2022: $471 · 2023: $336 · 2024: $125 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $460.36 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $341.31 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $335.38 | 2019-2024 | Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $283.88 | 2019-2023 | Trintellix |
| Allergan, INC. | $273.81 | 2019-2020 | |
| Abbvie INC. | $216.81 | 2021-2023 | Vraylar |
| Sunovion Pharmaceuticals INC. | $183.60 | 2019-2022 | |
| Lundbeck LLC | $176.85 | 2019-2021 | |
| Boston Scientific Corporation | $138.10 | 2023 | Watchman Access System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.76 | 2022-2023 | Caplyta |
| Avanir Pharmaceuticals, INC. | $67.11 | 2019-2021 | |
| Alkermes, INC. | $61.70 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $61.70 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $55.64 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $54.59 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $46.00 | 2021-2022 | |
| Shire North American Group INC | $44.27 | 2019 | |
| Corium, LLC | $39.07 | 2022 | |
| Zimmer Biomet Holdings, INC. | $33.78 | 2022 | |
| Bausch Health US, LLC | $26.79 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.46 | 2019 | |
| Noven Therapeutics, LLC | $11.57 | 2020 | |
| Eisai INC. | $11.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tonsing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.